Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19

Better international sequencing efforts are needed to track and respond to new SARS-CoV-2 variants

 

San Francisco, California, USA (July 15, 2021) — The lack of sequencing of SARS-CoV-2 variants by the U.S. and other countries is imperiling the global response to the COVID-19 pandemic, argues Dana Crawford of Case Western Reserve University in a new Viewpoint published July 15th in the journal PLOS Genetics.

Surveillance is essential to a successful and rapid response to disease outbreaks, but public health surveillance has traditionally focused on monitoring case numbers, hospitalizations and deaths. Advances in genome sequencing now allow us to track genetic variation in evolving viruses in unprecedented detail. However, despite the availability of sequencing in several countries, the adoption of genomics as a strategy for surveilling the SARS-CoV-2 virus, which causes COVID-19, has been slow, difficult and inconsistent. Crawford points out that, as of early April 2021, the U.S. ranked 33rd in the world in SARS-CoV-2 sequencing for variant surveillance. She says that historically, the Centers for Disease Control and Prevention (CDC) has not prioritized genomic research for public health, and this bias has created a gaping hole in our understanding of the real-time evolution of SARS-CoV-2 and the impact on disease transmission and severity.

Crawford cites insufficient funding, the lack of an effective sample tracking system and strict regulations on sample and data sharing as the causes of the inadequate sequencing efforts. Still, other countries, such as China and the U.K., have successfully overcome these challenges. The CDC recently committed more than $200 million to enhance sequencing, but Crawford points out that this late investment means that the U.S. lacks an organized database of patient information for COVID-19 studies. She cautions that investments in SARS-CoV-2 genomics need to continue and expand as new variants will likely arise due to variability in vaccination rates and adherence to COVID-19 precautions worldwide.

Given that SARS-CoV-2 is a novel zoonotic disease with no prior human infections, Crawford argues that sequencing and analysis are vital to understanding both the trajectory of the outbreak and its evolution. Provisions are also sorely needed to link genetic data to clinical and epidemiological data sources for public health research. Finally, she concludes that ongoing international sequencing efforts are still needed to understand and respond to this continually evolving virus that knows no international boundaries.

„COVID-19 control requires near real-time host-pathogen genomic and public health data to track how SARS-CoV-2 has evolved and how this evolution affects transmission and disease severity,“ Crawford adds. „US and global sequencing efforts have been too few and too disjointed, underscoring the need to engage with human genomics and integrate its technologies in emerging infectious disease public health responses.“

 

 

Peer-reviewed; Opinion piece / editorial

In your coverage please use this URL to provide access to the freely available article in PLOS Genetics:

http://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1009620

Citation: Crawford DC, Williams SM (2021) Global variation in sequencing impedes SARS-CoV-2 surveillance. PLoS Genet 17(7): e1009620. https://doi.org/10.1371/journal.pgen.1009620

Funding: This publication was made possible by the Clinical and Translational Science Collaborative of Cleveland (to DCC), UL1TR002548 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH Roadmap for Medical Research (to DCC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: SMW is a section editor of PGEN.

 

 


PLOS, 15.07.2021 (tB).

Schlagwörter:

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…